2009•Nutrition ReviewsRequires access

Hyperhomocysteinemia as a Risk Factor for Cardiovascular Disease in Patients Undergoing Hemodialysis

Joy A. Friedman, Johanna T. Dwyer

Abstract

Hyperhomocysteinemia exists among patients both in end-stage renal disease and on dialysis and may represent an additional risk factor for increased cardiovascular disease. Supplementation with folic acid may reduce, but not correct, hyperhomocysteinemia. Evidence that lowering blood homocysteine will lessen cardiovascular risk is being sought.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 22 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Hyperhomocysteinemia, Medicine, Homocysteine, Risk factor, Hemodialysis, Dialysis, Disease, Folic acid